Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 15/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | NMBR | P28336 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4682017 | 0.96 | SIRT2 (0.47) | SIRT2CYP11B1CYP11B2ENPP2NMBR | |
| SCHEMBL4695670 | 0.95 | SIRT2 (0.46) | SIRT2CYP11B1CYP11B2ENPP2NMBR | |
| SCHEMBL1040511 | 0.92 | SIRT2 (0.49) | SIRT2CYP11B1CYP11B2ENPP2NMBR | |
| SCHEMBL7972750 | 0.90 | SIRT2 (0.48) | SIRT2CYP11B1CYP11B2ENPP2NMBR | |
| SCHEMBL5891927 | 0.82 | SIRT2 (0.46) | SIRT2CYP11B1CYP11B2ENPP2NMBR | |
| SCHEMBL2490264 | 0.82 | SIRT2 (0.48) | SIRT2CYP11B1CYP11B2ENPP2NMBR | |
| SCHEMBL2796109 | 0.81 | SIRT2 (0.52) | SIRT2CYP11B1CYP11B2 | |
| SCHEMBL2032778 | 0.81 | SIRT2 (0.47) | SIRT2CYP11B1CYP11B2ENPP2NMBR | |
| SCHEMBL1309013 | 0.81 | SIRT2 (0.47) | SIRT2CYP11B1CYP11B2ENPP2 | |
| SCHEMBL8165853 | 0.81 | SIRT2 (0.47) | SIRT2CYP11B1CYP11B2ENPP2NMBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1748986-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-12-01 | — | — | EP | disclosed |
| EP-1318993-B1 | SUBSTITUTED IMIDAZOLES AS DUAL HISTAMINE H1 AND H3 AGONISTS OR ANTAGONISTS | SCHERING CORP (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1318994-B1 | SUBSTITUTED IMIDAZOLES AS DUAL HISTAMINE H1 AND H3 AGONISTS OR ANTAGONISTS | SCHERING CORP (US) | 2008-02-27 | — | — | EP | disclosed |
| EP-1748986-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ALDOSTERONE SYNTHASE INHIBITORS | Speedel Experimenta AG (CH) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005118541-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ALDOSTERONE SYNTHASE INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2005-12-15 | — | — | WO | disclosed |
| EP-1318996-B1 | SUBSTITUTED IMIDAZOLES AS DUAL HISTAMINE H1 AND H3 AGONISTS OR ANTAGONISTS | SCHERING CORP (US) | 2004-12-01 | — | — | EP | disclosed |
| US-6762186-B2 | USE TO TREAT ALLERGY, NASAL CONGESTION, INFLAMMATORY AND CENTRAL NERVOUS SYSTEM-RELATED DISEASES | SCHERING CORPORATION | 2004-07-13 | — | — | US | disclosed |
| EP-1318993-A2 | SUBSTITUTED IMIDAZOLES AS DUAL HISTAMINE H1 AND H3 AGONISTS OR ANTAGONISTS | Schering Corporation (US) | 2003-06-18 | — | — | EP | disclosed |
| EP-1318996-A2 | SUBSTITUTED IMIDAZOLES AS DUAL HISTAMINE H1 AND H3 AGONISTS OR ANTAGONISTS | Schering Corporation (US) | 2003-06-18 | — | — | EP | disclosed |
| EP-1318994-A2 | SUBSTITUTED IMIDAZOLES AS DUAL HISTAMINE H1 AND H3 AGONISTS OR ANTAGONISTS | Schering Corporation (US) | 2003-06-18 | — | — | EP | disclosed |
| US-6506756-B2 | For treatment of allergies, inflammatory and central nervous system related diseases | SCHERING CORPORATION | 2003-01-14 | — | — | US | disclosed |
| US-20020086859-A1 | Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists | SCHERING CORPORATION | 2002-07-04 | — | — | US | disclosed |
| US-20020082272-A1 | Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists | SCHERING CORPORATION | 2002-06-27 | — | — | US | disclosed |
| US-20020082278-A1 | Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists | SCHERING CORPORATION | 2002-06-27 | — | — | US | disclosed |
| WO-2002044141-A2 | SUBSTITUTED IMIDAZOLES AS DUAL HISTAMINE H1 AND H3 AGONISTS OR ANTAGONISTS | SCHERING CORPORATION (US) | 2002-06-06 | — | — | WO | disclosed |
| WO-2002024657-A2 | SUBSTITUTED IMIDAZOLES AS DUAL HISTAMINE H1 AND H3 AGONISTS OR ANTAGONISTS | SCHERING CORPORATION (US) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002024659-A2 | SUBSTITUTED IMIDAZOLES AS DUAL HISTAMINE H1 AND H3 AGONISTS OR ANTGONISTS | SCHERING CORPORATION (US) | 2002-03-28 | — | — | WO | disclosed |
| US-6355665-B1 | ANTIHISTAMINES, ANTIALLERGENS AND IRRITABLE BOWEL SYNDROME. | JAMES BLACK FOUNDATION LIMITED (GB) | 2002-03-12 | — | — | US | disclosed |
| US-6080871-A | ANTIHISTAMINES | JAMES BLACK FOUNDATION LIMITED (GB) | 2000-06-27 | — | — | US | disclosed |
| WO-1999005114-A2 | 1H-4(5)-SUBSTITUTED IMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS HISTAMINE H3 RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082278-A1 | Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists | HRH3, HRH4, HRH2 | SIRT2 826/4885CYP11B1 3429/4885CYP11B2 3038/4885 |
| US-20020082272-A1 | Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists | HRH3, HRH4, HRH2 | SIRT2 1028/4885CYP11B1 3504/4885CYP11B2 3118/4885 |
| US-20020086859-A1 | Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists | HRH3, HRH4, HRH2 | SIRT2 842/4885CYP11B1 4138/4885CYP11B2 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.